CEUS联合MRI增强扫描早期评价射频消融治疗原发性肝癌患者疗效研究*

doi:10.3969/j.issn.1672-5069.2023.06.032

Abstract

Abstract: Objective The aim of this study was to investigate the early evaluation of complete inactivation of tumors by contrast enhanced ultrasound (CEUS) and enhanced magnetic resonance imaging (MRI) scan after radiofrequency ablation (RFA) in patients with primary liver cancer (PLC). Methods 81 patients with PLC were encountered in our hospital between January 2019 and January 2022, and all underwent RFA. One month after the treatment, the CEUS and enhanced MRI scan were performed, and the consistency with digital subtraction angiography (DSA), as the gold standard was compared. Results Out of the 81 patients with PLC, the DSA examination showed the tumor foci was completely inactivated in 61 cases, with tumor residual in 20 cases; the sensitivity (Se), specificity (Sp) and accuracy (Ac) by CEUS evaluation were 91.8%, 85.0% and 90.1%, the Se, Sp and Ac by MRI scan were 96.7%, 95.0% and 96.3%, and the Se, Sp and Ac by CEUS and MRI combination evaluation were 98.4%, 100.0% and 98.8%. Conclusion The early evaluation of tumor inactivation by CEUS and enhanced MRI scan combination after RFA treatment in patients with PLC is efficacious, which might guide the clinicians to make appropriate measures for better outcomes.

Key words: Hepatoma, Radiofrequency ablation, Contrast-enhanced ultrasound, Enhanced magnetic resonance imaging, Therapy

Liu Sihong, Xie Lujia, Zhou Zhiming, et al. Early evaluation of complete inactivation of tumors by CEUS and enhanced MRI scan after radiofrequency ablation in patients with primary liver cancer[J]. Journal of Practical Hepatology, 2023, 26(6): 895-898.

References

[1] Guo W, Pang Y, Yao L, et al.Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [68ga] ga-fapi-04 pet/ct versus mri and [18f] -fdg pet/ct.Eur J Nucl Med Mol Imaging,2021, 48(5):1604-1617.
[2] Shao L, Wang X, Yu Y, et al.Comparative analysis of the efficacy and accuracy of magnetic resonance imaging (MRI) and contrast-enhanced ct for residual and new lesions after transcatheter arterial chemoembolization (TACE) in patients with primary liver cancer. Transl Cancer Res, 2021, 10(8):3739-3747.
[3] Rennert J, Wiesinger I, Beyer LP, et al.Color coded perfusion analysis and microcirculation imaging with contrast enhanced ultrasound (CEUS) for post-interventional success control following thermal ablative techniques of primary and secondary liver malignancies. Clin Hemorheol Microcirc, 2019, 73(1):73-83.
[4] Lu Q, Zhang XL, Han H, et al.Value of perfusion parameters for differentiating hepatocellular carcinoma and liver metastasis with hypervascularity and a normal hepatic background on contrast-enhanced ultrasound imaging. J Ultrasound Med, 2019, 38(10):2601-2608.
[5] Kim D, Lee JH, Moon H, et al.Development and evaluation of an ultrasound-triggered microbubble combined transarterial chemoembolization (TACE) formulation on rabbit vx2 liver cancer model. Theranostics, 2021, 11(1):79-92.
[6] 高军喜,谷昊,王雅婷,等.经皮局麻联合超声造影对困难肝癌RFA治疗的可行性及安全性分析.中华普通外科杂志,2019, 34(7):572-575.
[7] 中国抗癌协会肝癌专业委员会,中华医学会肝病学分会肝癌学组,中国抗癌协会病理专业委员会,中华医学会病理学分会消化病学组,中华医学会外科学分会肝脏外科学组,中国抗癌协会临床肿瘤学协作专业委员会,全国肝胆肿瘤及移植病理协作组.原发性肝癌规范化病理诊断指南(2015年版).中华肝脏病杂志,2015, 23(5):321-327.
[8] Choi SH, Jeon SK, Lee SS, et al.Radio-pathologic correlation of biphenotypic primary liver cancer (combined hepatocellular cholangiocarcinoma): changes in the 2019 who classification and impact on li-rads classification at liver MRI. Eur Radiol, 2021, 31(12):9479-9488.
[9] Yamada A, Oyama K, Fujita S, et al.Dynamic contrast-enhanced computed tomography diagnosis of primary liver cancers using transfer learning of pretrained convolutional neural networks: is registration of multiphasic images necessary. Int J Comput Assist Radiol Surg, 2019, 14(8):1295-1301.
[10] Bröker MEE, Taimr P, Vries Md, et al.Performance of contrast-enhanced sonography versus mri with a liver-specific contrast agent for diagnosis of hepatocellular adenoma and focal nodular hyperplasia. AJR, 2020, 214(1):81-89.
[11] Luz JHM, Gomes FV, Costa NV, et al.Bestflr trial: liver regeneration at CT before major hepatectomies for liver cancer-a randomized controlled trial comparing portal vein embolization withn-butyl-cyanoacrylate plus iodized oil versus polyvinyl alcohol particles plus coils. Radiology, 2021, 299(3):715-724.
[12] Hirooka M, Koizumi Y, Tanaka T, et al.Efficacy of combining electric-field and coronal-plane imaging to obtain ultrasound-ultrasound fusion images in monopolar radiofrequency ablation for patients with liver cancer. Hepatol Res, 2020, 50(8):985-995.
[13] Jin H, Chalkidou A, Hawkins M, et al.Cost-effectiveness analysis of stereotactic ablative body radiation therapy compared with surgery and radiofrequency ablation in two patient cohorts: metastatic liver cancer and hepatocellular carcinoma. Clin Oncol, 2021, 33(3):143-154.
[14] Yu C, Wu S, Zhao J, et al.Evaluation of efficacy, safety and treatment-related outcomes of percutaneous radiofrequency ablation versus partial hepatectomy for small primary liver cancer meeting the milan criteria: a systematic review and meta-analysis of randomized controlled trials. Clin Res Hepatol Gastroenterol, 2020, 44(5):718-732.
[15] Guo C, Liang H, Yuan W, et al.Analysis on the value of soluble intercellular adhesion molecule-1 (sicam-1), alpha fetoprotein (AFP), and aspartate aminotransferase/platelet ratio index (apri) in predicting the prognostic survival of patients with primary liver cancer after radiofrequency ablation. Ann Palliat Med, 2021, 10(4):4760-4767.
[16] Yamashita YI, Imai K, Kaida T, et al.Multimodal radiofrequency ablation versus laparoscopic hepatic resection for the treatment of primary hepatocellular carcinoma within milan criteria in severely cirrhotic patients: long-term favorable outcomes over 10 years Surg Endosc, 2019, 33(1):46-51.
[17] Lee S, Kim KW, Jeong WK, et al.Liver imaging reporting and data system category on magnetic resonance imaging predicts recurrence of hepatocellular carcinoma after liver transplantation within the milan criteria: a multicenter study. Ann Surg Oncol, 2021, 28(11):6782-6789.
[18] 汪玲,陆英慧,王天佑.靶向血管内皮生长因子受体2的超声造影对裸鼠肝癌皮下移植瘤模型中抗血管生成治疗反应的无创监测价值.中华肿瘤杂志,2020, 42(10):856-860.
[19] Koh DM, Ba-Ssalamah A, Brancatelli G, et al.Consensus report from the 9th international forum for liver magnetic resonance imaging: applications of gadoxetic acid-enhanced imaging. Eur Radiol, 2021, 31(8):5615-5628.
[20] 叶辰,任思谦,阿卜杜海拜尔·萨杜拉,等.钆塞酸二钠MRI增强在肝癌大块肝切除手术中的应用价值.中华外科杂志,2020, 58(10):765-769.

Early evaluation of complete inactivation of tumors by CEUS and enhanced MRI scan after radiofrequency ablation in patients with primary liver cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Yang RuiXu, Qi Minghua. Antiviral strategy of patients with chronic hepatitis B and concomitant metabolic-dysfunction-related fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(6): 773-776.
[2]	Zhong Jinlong, Shi Lin. MiR-556-3p affects the metastatic activity of HepG2 cells by regulating PTEN/AKT signaling pathway in vitro [J]. Journal of Practical Hepatology, 2023, 26(6): 781-784.
[3]	Song Tao, Xu Min, Dang Zilong, et al. Virologic and biochemical response to entecavir and interferon-α combination therapy in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(6): 785-788.
[4]	Gao Lijuan, Li Yongku, Dong Xinying, et al. Oral tenofovir amibufenamide administration in the treatment of patients with chronic hepatitis B didn’t impact renal functions [J]. Journal of Practical Hepatology, 2023, 26(6): 789-792.
[5]	Zhou Jiying, Xie Yuehong, Yu Cuixia. Decreased biochemical response to entecavir anti-viral therapy in patients with chronic hepatitis B and concomitant non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(6): 793-796.
[6]	Cao Bianchuan, Liu Mei, Ding Ping, et al. Efficacy and safety of glecaprevir/pibrentasvir in treating patients with HCV mono-infection and HIV/HCV co-infection [J]. Journal of Practical Hepatology, 2023, 26(6): 801-804.
[7]	Wang Zhuoya, Wu Yangpeng, Huang Yitao. Combination therapy of reduced glutathione and herbal medicine compound, Hugan Qingzhi tablet in treatment of patients with non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(6): 823-826.
[8]	Chen Yajun, Zhu Jing, Li Lu, et al. Peripheral blood regulatory B cell subset changes in patients with autoimmune hepatitis undergoing magnesium isoglycyrrhizinate and standard immunosuppressive therapy [J]. Journal of Practical Hepatology, 2023, 26(6): 835-838.
[9]	Yang Kaining, Wang Mengmeng, Wang Zhankun, et al. Combination of glutathione and tiopronin in the treatment of patients with drug-induced liver injury [J]. Journal of Practical Hepatology, 2023, 26(6): 839-842.
[10]	Wang Xinyue, Zhou Li, Dong JinLing, et al. Anticoagulant efficacy and safety comparison of nafmostat mesylate and heparin during double plasma molecular absorption system treatment in patients with liver failure [J]. Journal of Practical Hepatology, 2023, 26(6): 843-846.
[11]	Jiang Yachao, Yin Li, Yan Zhuang. Modified sandwich endoscopic selective varices devascularization in the treatment of cirrhotics with esophagogastric varices [J]. Journal of Practical Hepatology, 2023, 26(6): 863-866.
[12]	Yang Fan, Zhang Xiaojuan, Li Dan, et al. Risk factors of re-bleeding in patients with hepatitis B cirrhosis and esophagogastric varices bleeding within one year after gastroscopic sclerotherapy and tissue glue injection [J]. Journal of Practical Hepatology, 2023, 26(6): 875-878.
[13]	Liu Gongpan, Chen Tao, Ding Zhigang, et al. Efficacy of transcatheter arterial chemoembolization with CalliSpheres drug-loaded microspheres followed by radiofrequency ablation in the treatment of patients with primary liver cancer [J]. Journal of Practical Hepatology, 2023, 26(6): 879-882.
[14]	Yang Wan, Ding Li, Luo Ke, et al. Clinical implications of cancerous tissue CK7 and glypican-3 expression in patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2023, 26(6): 883-886.
[15]	Mo Chunming, Huang Dejia, Wei Huizhang, et al. Predictive efficacy of serum IL-33 and procalcitonin levels for bacterial infection in primary liver cancer patients with fever after TACE [J]. Journal of Practical Hepatology, 2023, 26(6): 887-890.